You are here:-Biospectal

Democratizing blood pressure monitoring

Complications from high blood pressure kill 10 million people a year. Studies show that while control has plateaued in developed countries, in the developing world prevalence continues to grow while awareness remains low. As early detection is essential, more accessible and frequent monitoring is now seen as vital. What if it were possible to put

Democratizing blood pressure monitoring2021-10-08T08:26:08+01:00

Smartphone Blood Pressure App Publishes Clinical Validation

The team behind the OptiBP app that uses a smartphone’s camera to accurately record blood pressure has announced the publication of clinical study results that validate the accuracy of the technology. Conducted by the team of Prof. Patrick Schoettker at CHUV Lausanne University hospital and the University of Lausanne UNIL in Switzerland, the study results confirm Biospectal OptiBP meets the ISO 81060-2

Smartphone Blood Pressure App Publishes Clinical Validation2021-09-30T10:37:13+01:00

Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink

Remote patient monitoring and biosensing company will use investment to scale its OptiBP™ blood pressure measurement and monitoring product and operations worldwide; Renowned interventional cardiologist and inventor, Dr. Fred St. Goar, MD and SeedLink's Tim Juergens appointed to Biospectal's Board of Directors LAUSANNE, Switzerland and SAN FRANCISCO, July 21, 2021 /PRNewswire/ -- Biospectal SA, the remote patient monitoring and biosensing software

Biospectal Raises $4.3M Seed Funding Led by Digital Health Investor, SeedLink2021-09-30T10:37:22+01:00